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ABSTRACT
Skin cancers are an incredibly common malignancy in the United States. A direct relationship
between lifetime ultraviolet radiation and subsequent development of skin cancers has been
established. Of these, non-melanoma skin cancers, including squamous cell carcinoma and
basal cell carcinoma, are the most common. Cutaneous squamous cell carcinomas (cSCCs)
located on the lip are concerning given their increased risk of recurrence and metastasis. Given
this increased risk of morbidity and mortality, it is essential to continue to monitor patients
with a history of these high-risk skin cancers with at least annual full-body skin exams. This
study identified approximately 25% of patients without any follow-up for a skin check. This list
was then securely provided to office staff to prioritize contacting these patients for follow-up.
INTRODUCTION
Currently, it is estimated that one in five Americans will develop skin cancer throughout
their lifetime, with approximately 1 million new skin cancer cases occurring in the United States
alone each year (Rigell, 2008). Non-melanoma skin cancers including cutaneous squamous cell
carcinoma (cSCC) and basal cell carcinoma compromise the majority of these skin cancers
(Clayman et al, 2005). Most cSCCs have a good overall prognosis and are easily cured by surgical
excision or other local methods, however, a subset demonstrate propensity for higher risk of
morbidity and mortality, including cSCC of the lip (Mullen et al, 2006). One study demonstrated
that cSCC of the lip have an elevated risk of metastasis of 14%. This is compared to a baseline
risk of approximately 5% for cSCC occurring on other sun-exposed areas (Rowe et. al, 1992).
Research has also demonstrated patients diagnosed with a non-melanoma skin cancer have a
40.7% 5-year probability and a 59.6% 10-year probability of developing a subsequent skin

cancer (Wehner et al, 2015). Given these risks, it is important to have continuous follow-up to
continue surveillance of high-risk skin cancer patients and to identify future skin cancers that
may occur. A guideline published in 2017 for care of cSCC recommends at least yearly in-office
screening skin exams by a dermatologist, adjusting this frequency based on individual risk (Alam
et al, 2018). Therefore, it is important to identify patients with a history of high-risk cSCC, and
ensure they are receiving annual full body skin exams as recommended for thorough
surveillance of skin cancer recurrence and/or metastasis. This project aimed to improve cancer
surveillance by the UVMMC Division of Dermatology for patients with cSCC of the lip, a high-risk
skin cancer, particularly in the setting of delayed follow-up of care in the setting of the novel
COVID-19 pandemic.

METHODS
This study was a quality improvement study conducted at the University of Vermont
Medical Center Division of Dermatology. This study was conducted in the time of wide-spread
office closure in the setting of the novel COVID-19 pandemic. Exclusion criteria included patient
death and patients with more than one skin cancer type. A manual chart review was conducted
of 244 cSCCs of the lip. Of these, 193 unique patients with cSCC of the lip were included in the
study. Patients were further divided into two groups: those who had their SCC site evaluated by
a UVMMC dermatology physician or PA within the past year (since 2/20/2019) and those who
had not been seen in the past year (since 2/20/2019). These individuals were further classified
by those who follow-up primarily with our office for skin checks and those who primarily followup with an outside provider or non-dermatologic specialty for skin checks. Following
identification of individuals with prior cSCC of the lip who had not received a full-body skin
exam at our clinic within the past year, this list was then securely provided to office staff at the
University of Vermont Medical Center Dermatology Office to prioritize these high-risk skin
cancer patients following the return to clinical duties of dermatologic providers.

RESULTS

Refer to figure 1 for further clarification of exclusion and inclusion criteria. Overall, 36
patients were identified as deceased. These patient deaths were unrelated to their skin cancer
history. Additionally, 15 patients were identified as having more than one type of skin cancer.
Furthermore, 27.5% of patients were identified as having follow-up at UVMMC within the next
year. This is artificially low as many appointments are scheduled 1-3 months in advance. In
addition, 40.5% of patients see an outside dermatologist and 12% see a non-dermatologic
provider for skin checks. Many patients are referred to UVMMC for definitive surgery through
our Mohs Department and then return to the referring provider for continued care, as is
standard practice. We identified 25% of patients with no known appropriate follow-up. These
records were manually reviewed to determine if the patient appears overdue for cancer
surveillance. If this was the case, they were offered a priority follow-up appointment at the
time of office re-opening.

DISCUSSION
In the setting of the novel COVID-19 pandemic, offices across the United States
experienced closure for the health of providers and patients and to further implement a plan
for safe practices. These closures and wide-spread fear of illness is likely to have resulted in
delayed presentation to care and/or delayed patient follow-up. Given the need for regular inperson follow-up of patients with high-risk skin cancer, it is prudent to identify patients that
were overdue for skin cancer screening. This quality improvement study helped identify
patients with high-risk cSCC that were overdue for dermatologic cancer surveillance. We then
used cancer risk-stratification to assist office staff in prioritization of high-risk patient
scheduling. A limitation of this study was that it did not track patients after initial identification
to determine if patients were more likely to follow-up in our clinic following contact by staff.
Future studies would be beneficial to determine if this study resulted in improved patient
follow-up and outcomes.

Figure 1. Patient inclusion and exclusion criteria.
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